%0 Journal Article
%A Brendel, Matthias
%A Barthel, Henryk
%A van Eimeren, Thilo
%A Marek, Ken
%A Song, Mengmeng
%A Palleis, Carla
%A Gehmeyr, Mona
%A Beyer, Leonie
%A Fietzek, Urban
%A Respondek, Gesine
%A Sauerbeck, Julia
%A Nitschmann, Alexander
%A Zach, Christian
%A Hammes, Jochen
%A Barbe, Michael T
%A Onur, Oezguer
%A Jessen, Frank
%A Saur, Dorothee
%A Schroeter, Matthias L
%A Rumpf, Jost-Julian
%A Rullmann, Michael
%A Schildan, Andreas
%A Patt, Marianne
%A Neumaier, Bernd
%A Barret, Olivier
%A Madonia, Jennifer
%A Russell, David S
%A Stephens, Andrew
%A Roeber, Sigrun
%A Herms, Jochen
%A Bötzel, Kai
%A Classen, Joseph
%A Bartenstein, Peter
%A Villemagne, Victor
%A Levin, Johannes
%A Höglinger, Günter
%A Drzezga, Alexander
%A Seibyl, John
%A Sabri, Osama
%T Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy.´ment
%J JAMA neurology
%V 77
%N 11
%@ 2168-6149
%C Chicago, Ill.
%I American Medical Association
%M DZNE-2021-00307
%P 1408 -
%D 2020
%X Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future interventional trials against tau in PSP would strongly benefit from biomarkers that support diagnosis.To investigate the potential of the novel tau radiotracer 18F-PI-2620 as a biomarker in patients with clinically diagnosed PSP.In this cross-sectional study, participants underwent dynamic 18F-PI-2620 positron emission tomography (PET) from 0 to 60 minutes after injection at 5 different centers (3 in Germany, 1 in the US, and 1 in Australia). Patients with PSP (including those with Richardson syndrome [RS]) according to Movement Disorder Society PSP criteria were examined together with healthy controls and controls with disease. Four additionally referred individuals with PSP-RS and 2 with PSP-non-RS were excluded from final data analysis owing to incomplete dynamic PET scans. Data were collected from December 2016 to October 2019 and were analyzed from December 2018 to December 2019.Postmortem autoradiography was performed in independent PSP-RS and healthy control samples. By in vivo PET imaging, 18F-PI-2620 distribution volume ratios were obtained in globus pallidus internus and externus, putamen, subthalamic nucleus, substantia nigra, dorsal midbrain, dentate nucleus, dorsolateral, and medial prefrontal cortex. PET data were compared between patients with PSP and control groups and were corrected for center, age, and sex.Of 60 patients with PSP, 40 (66.7
%K Aged
%K Biomarkers: metabolism
%K Cross-Sectional Studies
%K Diagnosis
%K Female
%K Fluorine Radioisotopes: pharmacokinetics
%K Gray Matter: diagnostic imaging
%K Gray Matter: metabolism
%K Humans
%K Male
%K Middle Aged
%K Multiple System Atrophy: diagnostic imaging
%K Multiple System Atrophy: metabolism
%K Parkinson Disease: diagnostic imaging
%K Parkinson Disease: metabolism
%K Positron-Emission Tomography: standards
%K Pyridines: pharmacokinetics
%K Sensitivity and Specificity
%K Severity of Illness Index
%K Supranuclear Palsy, Progressive: diagnostic imaging
%K Supranuclear Palsy, Progressive: metabolism
%K tau Proteins: metabolism
%K ((18)F)PI-2620 (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%K Fluorine Radioisotopes (NLM Chemicals)
%K Pyridines (NLM Chemicals)
%K tau Proteins (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33165511
%2 pmc:PMC7341407
%R 10.1001/jamaneurol.2020.2526
%U https://pub.dzne.de/record/154698